BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Abady MM, Jeong J, Kwon H. Development and validation of an analytical method using liquid chromatography-tandem mass spectrometry for the therapeutic drug monitoring of seven cardiovascular drugs in clinical usage. Journal of Chromatography B 2022. [DOI: 10.1016/j.jchromb.2022.123552] [Reference Citation Analysis]
2 Cogan RC, El-Matary BW, El-Matary WM. Therapeutic drug monitoring for biological medications in inflammatory bowel disease. Saudi J Gastroenterol 2022;28:322-31. [PMID: 35343213 DOI: 10.4103/sjg.sjg_3_22] [Reference Citation Analysis]
3 Rosseto-welter EA, D’argenio-garcia L, Blasco Tavares Pereira Lopes F, Zulim Carvalho AE, Flaquer F, Severo-lemos V, Viero Nora CC, Steinwurz F, Pires Garcia Oliveria L, Aloia T, Rizzo LV, Pitangueira Mangueira CL, Carvalho KI, Gendron FP. Biologic Agents in Crohn’s Patients Reduce CD4+ T Cells Activation and Are Inversely Related to Treg Cells. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-9. [DOI: 10.1155/2022/1307159] [Reference Citation Analysis]
4 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
5 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
6 Lodhia N, Rao S. Updates in therapeutic drug monitoring in inflammatory bowel disease. World J Gastroenterol 2022; 28(21): 2282-2290 [DOI: 10.3748/wjg.v28.i21.2282] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pu D, Zhang Z, Feng B. Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. Front Pharmacol 2022;13:906419. [DOI: 10.3389/fphar.2022.906419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Danese S, Peyrin-Biroulet L. Evolution of IL-23 Blockade in Inflammatory Bowel Disease. J Crohns Colitis 2022;16:ii1-2. [PMID: 35553668 DOI: 10.1093/ecco-jcc/jjab188] [Reference Citation Analysis]
9 Wang MY, Zhao JW, Zheng CQ, Sang LX. Therapeutic drug monitoring in inflammatory bowel disease treatments. World J Gastroenterol 2022; 28(15): 1604-1607 [DOI: 10.3748/wjg.v28.i15.1604] [Reference Citation Analysis]
10 Truta B. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World J Gastroenterol 2022; 28(13): 1380-1383 [DOI: 10.3748/wjg.v28.i13.1380] [Reference Citation Analysis]
11 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Retnakumar SV, Geesala R, Bretin A, Tourneur-Marsille J, Ogier-Denis E, Maretzky T, Thu Nguyen HT, Muller S. Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases. J Autoimmun 2022;128:102814. [PMID: 35298976 DOI: 10.1016/j.jaut.2022.102814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Santiago M, Dias CC, Alves C, Ministro P, Gonçalves R, Carvalho D, Portela F, Correia L, Lago P, Magro F. The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review. Inflamm Bowel Dis 2022:izab334. [PMID: 35179190 DOI: 10.1093/ibd/izab334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Huo X, Li D, Wu F, Li S, Qiao Y, Wang C, Wang Y, Zhou C, Sun L, Luan Z, Yan Q, Wang J, Zhang Y, Zhao T, An Y, Zhang B, Tian X, Yu Z, Ma X. Cultivated human intestinal fungus Candida metapsilosis M2006B attenuates colitis by secreting acyclic sesquiterpenoids as FXR agonists. Gut 2022:gutjnl-2021-325413. [PMID: 35173042 DOI: 10.1136/gutjnl-2021-325413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wang S, Huang J, Tan KS, Deng L, Liu F, Tan W, Dominguez Perles R. Isosteviol Sodium Ameliorates Dextran Sodium Sulfate-Induced Chronic Colitis through the Regulation of Metabolic Profiling, Macrophage Polarization, and NF-κB Pathway. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/4636618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bálint A, Lovász BD. Editorial: Game Changers in Inflammatory Bowel Diseases. Front Med (Lausanne) 2021;8:795597. [PMID: 34869508 DOI: 10.3389/fmed.2021.795597] [Reference Citation Analysis]
17 Vaughn BP. A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease. J Clin Med 2021;10:4990. [PMID: 34768509 DOI: 10.3390/jcm10214990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Majidova K, Handfield J, Kafi K, Martin RD, Kubinski R. Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review. Genes (Basel) 2021;12:1465. [PMID: 34680860 DOI: 10.3390/genes12101465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Jampala N, Jain A, Herfarth HH, Long MD, Weaver KN, Barnes EL. Personalized Best: Toward Improving Care in Ulcerative Colitis. Dig Dis Sci 2021;66:3736-9. [PMID: 34463883 DOI: 10.1007/s10620-021-07221-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Grasmeier MK, Langmann AF, Langmann P, Treiber M, Thaler MA, Luppa PB. Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases. Therap Adv Gastroenterol 2021;14:17562848211037849. [PMID: 34434255 DOI: 10.1177/17562848211037849] [Reference Citation Analysis]
21 Massimino L, Lamparelli LA, Houshyar Y, D’alessio S, Peyrin-biroulet L, Vetrano S, Danese S, Ungaro F. The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework. Nat Comput Sci 2021;1:511-5. [DOI: 10.1038/s43588-021-00114-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
22 Liu H, Lu C, Han L, Zhang X, Song G. Optical – Magnetic probe for evaluating cancer therapy. Coordination Chemistry Reviews 2021;441:213978. [DOI: 10.1016/j.ccr.2021.213978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Massimi D, Barberio B, Bertani L, Costa F, Ferronato A, Facchin S, Cardin R, Cingolani L, Casadei C, D'Incà R, Zingone F, Savarino EV. Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. Therap Adv Gastroenterol 2021;14:17562848211023384. [PMID: 34249147 DOI: 10.1177/17562848211023384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sriranganathan D, Segal JP, Garg M. Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment. Frontline Gastroenterol 2022;13:168-70. [DOI: 10.1136/flgastro-2021-101881] [Reference Citation Analysis]
25 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
26 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
27 Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, García-Otero X, Antúnez-López JR, Ruibal Á, Varela-Correa JJ, Aguiar P, Basit AW, Otero-Espinar FJ, González-Barcia M, Goyanes A, Luzardo-Álvarez A, Fernández-Ferreiro A. 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease. Biomedicines 2020;8:E563. [PMID: 33276641 DOI: 10.3390/biomedicines8120563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]